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Background
Breast cancer is the most common cancer in females worldwide [1, 2] . Significant progress in prophylaxis, diagnosis and management of breast cancer has been made, especially in the last decade [3, 4] . However, female deaths by breast cancer did not decrease since advances in treatment merely compensated for the increasing incidence originating from demographical development and lifestyle changes [5, 6] . Distant metastases are still the leading cause of death in breast cancer patients [7, 8] .
functioning. Studies have demonstrated that at least one SRE occurs in nearly 50% of patients with bone metastases of breast cancer [14, 15] . Given the high prevalence of breast cancer, the population wide burden of BM is considerable. Thus, it is of immense important to analyze SREs and BM in the context of diagnosis, therapy and follow up.
Management options of breast cancer are based on surgical interventions, RT, neo-and adjuvant chemotherapy (ChT), hormonal therapy (HT) or molecular-targeted therapy (MT). The optimal, personalized management however, varies between patients according to cancer entity and physical status of the patient. In consequence comparability of patients with BM in clinical trials is limited. Furthermore few single-center, multi-center, and population-based studies specifically reporting BM and SREs exist. So far the systematic review or metaanalysis of these data is lacking. Therefore, we conducted review, focusing on incidence, risk factors, prognostic characteristics, management and outcome of BM and SREs in breast cancer patients. Our data provide the first coherent dataset that can be used for adjustments in care of breast cancer patients with BM and SREs in order to assure the best possible outcome, as well as to avoid an over-or under-treatment with BM and SREs.
Methods
Several breast surgeons, a medical oncologist and a medical statistician formed the panel to develop the search, selection, and review strategies, based on guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) [16, 17] .
Sources and search strategy
Literature research was performed independently by two trained reviewers (GF.H. and E.B.) using Pubmed, Web of Science, EMBASE OvidSP and EBSCO Academic Search Complete for articles published between 2000 and 2017 on English-language studies related to breast cancer, BM and SREs. The search was conducted using Medical Subject Headings (MeSH) or keywords, and when appropriate, search terms. Search terms were Boolean search criteria and included "Breast Neoplasms", "Breast Cancer", "Breast Carcinoma" OR "Breast Tumor*" and "Bone metastases", "Bone metastasis", "Metastasis of Bone", "Metastases of Bone", "Skeletal metastases", "Skeletal metastasis", "Skeletal complication*" OR "Skeletal-related event*". Further manuscripts were identified from reference lists of the primary papers. The last search was performed on June 11th, 2017. Detailed search methods are provided in the supplemental file (Appendix A-D).
Eligibility criteria
The records obtained from the literature search, containing titles and abstracts of the reviews, were exported into Refworks. First, duplicates were identified and removed from the pool of bibliographic records. Then, two trained investigators (GF.H. and E.B.) independently screened all retrieved abstracts and titles to determine articles that were ''potentially'' and deemed ''relevant'' references. Afterwards, two further reviewers (W.Y., H.W.) independently reviewed the full articles, using the following inclusion criteria: (1) single-center, multi-center or population-based clinical studies, focusing on breast cancer patients with BM; (2) studies that provided clinical information and specific data on the outcome of patients with BM from breast cancer. Studies were excluded if (1) they were single case reports, regular reviews or systematic review articles; (2) clinical trials focusing on breast cancer treatment; (3) studies on metastatic breast cancer focusing on visceral metastases; (4) investigating other cancers besides metastatic breast cancer. Disagreements were resolved by consulting with three additional reviewers (W.Z., Z.Y., H.Z.). When studies of overlapping groups of patients were identified, only the most recent studies were retained, with the notable exception of earlier studies presenting analyses that were not repeated in the most recent study.
Quality assessment
Two reviewers (C.Z. and GX.H.) independently assessed the quality of all included studies according to the Newcastle-Ottawa Scale (NOS) [18, 19] . The NOS has been developed to assess the quality of case--control and cohort studies, containing three parameters of quality that included: (1) selection; (2) comparability; and (3) exposure/ outcome assessment. Studies that achieved five or more points were considered to be of high quality. Any discrepancies between reviewers were addressed by a joint reevaluation of the original article.
Data abstraction
Two investigators (GF.H. and C.Z.) independently abstracted the data from the included articles. First author's name, publication year of the article, patients' data (demographics, tumor characteristics, BM) were extracted from each study. Any univariate and multivariate analysis for risk factors for BM and SREs or prognostic factors affecting survival in patients with breast cancer BM were tabulated. Whenever possible, diagnostics of BM, development of SREs, treatment information and prognostic outcomes were extracted. If these data were not mentioned explicitly in the manuscripts (e.g. number of SREs), they were extrapolated from graphs, tabulated proportions of events or from subgroup analyses. Any disagreements were discussed to reach a consensus agreement.
Results

Literature search
The literature search yielded 2469 bibliographic records. Of this initial pool of records, 2280 were excluded after the first screen of the titles and abstracts. Following the full-text review, 156 studies were rejected for being out of scope. Of the remaining 33 records, nine were removed applying the exclusion criteria. The final set of bibliographic records reviewed was composed of 24 studies (Fig. 1 ).
Assessment of methodologic quality
The results of the quality assessment according to the NOS are shown in supplemental file (Appendix E). In total, 24 studies were included and all of which were assessed as high quality: One study [24] was rated with a NOS score of six, eight studies [23, 26, 28, 33, 36, 37, 41, 42] with a NOS score of seven, six studies [21, 22, 32, 34, 39, 40] with a NOS score of eight, seven studies [20, 25, 27, 31, 35, 38, 43] with a NOS score of nine, and two studies [29, 30] with a NOS score of ten.
Characteristics of the studies
Characteristics of the studies regarding study type and sample size, BM occurrence rates, patient demographics, tumor histopathological findings and clinical stage, estrogen receptor (ER) expression status, progesterone receptor (PR) expression status, epidermal growth factor receptor 2 (HER2) status, follow-up period are described in Table 1 . The 24 studies selected according to the inclusion criteria were published between 2000 and 2016. The median follow-up period ranged from 1.12 [21] to 12.50 years [20] . The BM occurrence rates ranged from 4.1% [40] to 30% [30] . The number of patients enrolled ranged from 48 [37] to 7189 patients [32] , of whom only one was male [23] . The median patients age at the time of diagnosis of breast cancer ranged from 46 [38] to 75 [32] . Premenopausal status reported in eight studies ranged from 13% [39] to 80% [30] . In total, hormone receptor (ER and/or PR) positive breast cancer was most common, followed by HER2 (ER-PR-) positive breast cancer and triple negative breast cancer (TNBC). At the time of diagnosis, most breast cancer patients had TNM stage I-III. Synchronous bone-only metastases at the time of diagnosis were reported in four studies [22, 33, 34, 39] .
Incidences of BM
Incidences of BM reported as new diagnosis of BM, the length of BMfree interval (BMFI), the number and sites of BM, organ metastases other than BM could be extracted from 17 studies ( Table 2) . In these 17 studies, the most common imaging modality for diagnosing the BM was bone scintigraphy (BS), followed by computed tomography (CT), magnetic resonance imaging (MRI) and direct radiography (DR). Positron emission tomography-CT (PET/CT) was reported as a diagnostic method for BM in two studies [27, 31] . Bone biopsy (Bb) and fine-needle aspiration biopsy (FNAB) were used as diagnostic methods in only one study [28] . The mean time of length of BMFI ranged from 0.91 [23] to 4.20 years [36] .
Analysis of risk factors for BM
Seven of the included 24 studies were subjected to analyses of risk factors for BM. Five studies performed both univariate and multivariate analyses [20, 25, 27, 30, 35] , while in two further studies only univariate analysis was performed [37, 41] . A summary is illustrated in Table 3 . Increased risk for BM was associated with young age, higher TNM stages and higher grades [25, 27, 30, 35, 41] . The menopausal state did not seem to affect BM formation [27, 35] . Three studies [25, 35, 37] indicated that invasive lobular carcinoma was an independent risk factor for developing BM: Harries et al. [25] showed in their multivariate analysis a HR of 1.26 (1.03-1.55). Regarding the impact of hormone receptor status (ER, PR, HER2) on BM, results were inconsistent: some reports [30, 41] suggested that ER and or PR positivity had susceptibility to BM; whereas other data [25, 35, 37] claimed that ER and PR status did not affect the formation of BM. One study [27] even showed that BM was less likely to occur in PR-positive, and most likely to occur in HER2-positive breast cancer patients.
Developments of SREs
Breast cancer patients predominantly present with osteolytic BM, which leads SREs, included BP, PF, SCC, and TIH. The most frequent therapeutic measures include bone-modifying agents (BMAs), RT and surgery. Characteristics of SREs regarding the occurrence, the ratio of total and specific SREs, SERs-free interval (SREFI) and the first-line therapy are summarized in Table 4 . The majority of patients with SREs received BMA as first systemic treatment after the diagnosis of bone disease [22, 24, 28] . Some patients also received ChT, HT or MT for visceral metastases at the diagnosis of SREs [24, 29, 31] . Patients with SREs such as BP, PF, SCC were more likely to receive RT or a surgical intervention [21, 40, 42] .
Analysis of risk factors for SREs
A summary of the univariate and multivariate analysis of risk factor for SREs is shown in Table 5 . As for the occurrence of SREs, two single factor [22, 43] and two multi-factor articles [29, 36] . One article [22] specifically discussed the PF, while other [36, 43] focused on the occurrence of SREs were analyzed. Main risk factors for SREs were the clinical stage of the disease, age, menstrual status, tissue grade and molecular classification [27, 29] . Moreover, BM in osteoporotic patients, occurrence of BM as first metastases, multiple BM, disease free interval (DFI) less than 3 years and presence of BM longer than 2 years [29, 36, 43] . In terms of molecular markers, patients with positive Ca153 and ALP (combined) more prone to SREs [22, 27, 43] .
Analysis of survival in breast cancer patients with BM
Sixteen studies evaluated predictors of survival in breast cancer patients with BM. Results are summarized in Table 6 : In univariate and/ or multivariate analysis, the main predictors included age, menopausal status, clinical stage, histological type, ER/PR/HER2 status, Karnofsky Performance Status score (KPS), BMFI, number of BM, visceral metastases and treatment received. After the initial diagnosis of BM, the median survival for breast cancer patients was ranging from 2.1 [42] to 4 years [22] . However many trials did not strictly divide between patients with bone-only vs. multiple metastatic sites. The latter had a far worse survival and recurrences were more frequent. Since a number of prognostic factors at breast cancer diagnosis retained prognostic significance for survival following the first diagnosis of metastatic breast cancer, patients with bone-only metastasis of breast cancer with favorable tumor characteristics had a better outcome [20, 25, 41] .
Discussion
To date, although recent population-based research has improved Table 1 Cohort characteristics of patients at time of diagnosis of breast cancer included studies.
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Year Country [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] our empirical understanding of the occurrence of BM secondary to breast cancer, and have quantified the impact of BM and subsequent SREs on breast cancer survival, important gaps in the data remain [20, 32] . Especially real-world data on prognostic and predictive factors among patients', tumor's and treatment's characteristics are limited. Given the heterogeneity of patients with breast cancer, such information may help to select the most appropriate treatment strategy and thereby improving patient outcome and cost effectiveness [21, 44] . We therefore conducted a systematic review and analysis in order to describe the incidence, identify risk factors for BM and SREs and their prognostic value in breast cancer patients. In addition, we have focused on BMFI and SREFI, as well as radiologic imaging and the first line therapy. Our aim was to provide results that will improve understanding of prognostic and predictive factors may enable delivery of a more personalized treatment for the individual patient and a more costeffective use of health care resources [45] . Our analysis included 24 studies, 22 of which were of a retrospective nature. The demographic analysis, as well as the analysis of patients' characteristics (distribution of the age, tumor type etc.), was reflecting the general population, thus the real world data.
Characteristics and risk factors of BM
The incidence of BM in breast cancer patients remained at about 70% over decades from early 1960s to 1990s [46] . Over the last 30 years, advances in early detection and evolving treatment options led to a noticeable fall in incidence [47] . Overall, the occurrence rate of BM in breast cancer patients in our study ranged from 4.1% [40] to 30% [30] . BM diagnosis was made mostly via scintigraphy and CT scans [48] . Moreover, BM most commonly affected the axial skeleton [49] . The reason for this phenomenon has not been fully understood yet, however, it is assumable that molecular and cellular biological characteristics of the tumor cells and the tissues to which they metastasize are of importance and influence the pattern of metastatic spread [50] . Several risk factors of BM showed conflicting or non-definitive associations, especially the hormone receptor status [20, 30, 35, 37] . The high heterogeneity in study populations, cancer treatment, and study methodology may explain the conflicting results. Interestingly, our analysis showed that the menopausal status had no influence on the development of BM -suggesting that the protective influence of estrogen on bones density was not protecting against tumor spread in the bones [27, 35] . Other factors such as gene signatures, molecular changes along tumorigenesis and therapy, as well as the bone turnover might also influence the development of BM [51] . The development of algorithms to determine each patient's individual risk for BM should in turn trigger the use of specific therapies in order to increase bone disease free interval. Further research on this topic is, therefore, extremely relevant for the daily practice [25, 52] .
Characteristics and risk factors of SREs
In randomized trials in advanced breast cancer, one of the major SREs occurs on average every 3-6 months after the onset of BM. In the studies included in our review, the mean SREFI, however, ranged from 25 days [27] to 3.41 years [22] . There are two main potential explanations for the significant differences. One reason could be that former studies [27] included patients with metastatic breast cancer with metastases other than BM and who were at an intermediate or high risk of recurrence, while the later studies [22] focused on boneonly metastatic patients and BF as the main SREs. BP however is also a very imminent SRE that causes limitations of the quality of life (QoF) and develops into a chronic condition [29, 53, 54] .
Based on the real world data, we were able to identify a number of risk factors for SREs occurrence in BM breast cancer patients. This observation is in accordance with a general knowledge. Regrettably, major trials did not mention important characteristics of the patients, Incidences of bone metastases in breast cancer patients in included studies. such as low body mass index (BMI), presence or absence of sarcopenia or cachexia, intake of analgetics etc. In other cancers, such as multiple myeloma, these factors have shown a prognostic significance for the development of SREs [55, 56] . Further research on these aspects is warranted.
BMAs Management of BM
Most BM patients in our study had been treated with BMAs. The approved BMAs include bisphosphonates such as pamidronate, zoledronic acid, and denosumab etc. The current American Society of Clinical Oncology (ASCO) evidence-based clinical practice guidelines 
NA
There was a significant association between BM and lower grade tumors (P = 0.019), ER-positive tumors (P < 0.0001) and the lymph node stage of the primary tumor (P = 0.047).
BM, bone metastases; T, tumor size; N, nodal status; pN, pathologic nodal status; M, metastatic status; ER, estrogen receptor; PR, progesterone receptor; HER2: human epidermal growth factor receptor 2; UA, uivariate analysis; MA, mltivariate analysis; NA, not available.
Table 4
Developments of skeletal-related events in breast cancer patients in included studies. [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] for the use of bisphosphonates in breast cancer recommend a therapy for patients with evidence of metastatic bone destruction in order to prevent further destruction and SREs [57] . Nevertheless, there are a number of open questions in clinical practice, which are still not covered by the guidelines, for example, no clear recommendations on the treatment duration, dosage-modification and administration frequency. Additionally, the adjuvant administration of bisphosphonates is still controversial since long-term observations on risk profiles, especially for elderly and multi-morbid patients, are sparse [58] . Recently, however, an extremely positive effect has been shown: Adding zoledronate in postmenopausal women under letrozole for example improved the DFS significantly, showing less subsequent BM in the immediate-zoledronate group versus the delayed-zoledronate group [59] . Moreover, for patients at an increased risk of anticancer therapy induced loss of bone mass, an osteoprotection with bisphosphonates are to be critically discussed [60] . Currently, there are several studies under run, such as the REDUSE study of the Swiss Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK, Swiss Group for Clinical Cancer Research).
Refs. SREs N(%) SREFI (range) yr BP N (%) PF N (%) SCC N (%) TIH N (%) RT N (%) Sur N (%) First-line Therapy for BM N (%)
It must be noted that comparison of the benefits of BMAs between real world and clinical trial populations is important, for a number of reasons. Firstly, the frequency of radiological investigations is likely significantly less for patients treated in routine clinical practice compared to those entering clinical trials. [27] . In addition, clinical trial patients usually have a better performance status due to restrictive inclusion criteria. Moreover, most of the patients enrolled in BMAs trials have metastatic disease confined to skeleton, while in real world, patients often suffer from a more spreaded disease. It must also be noted that bisphosphonates are relatively expensive supportive care drugs, and the criterion of percentage (person-year) for the use of bisphosphonates to prevent BM should be required with regard to cost-effectiveness [61, 62] .
Prognostic value of BM
Establishing the prognostic value of BM in breast cancer patients faces tremendous challenges. Firstly, trials mostly focus on anticancer treatment options and outcomes, predominantly in non-metastatic patients. Secondly, a concept of randomized studies focusing on survival in breast cancer patients with only BM would demand very strict eligibility criteria, extrapolation from various accompanying factors such as comorbidities, demographics etc. and presumably not achieve a representative n-number (since bone-only metastasis are believed to occur in 17-37% of patients with distant metastasis). In addition, nearly all metastatic patients have received some kind of treatment prior to the diagnosis of BM. Advanced breast cancer is per se very complex in a molecular, biological and therapeutic aspect. Patients not only suffer from BM, but can also be entrapped in a vicious circle of aggressive therapies with bone thinning as side effect and resulting susceptibility to SREs [63, 64] . As for the survival, predictive factors show a certain overlap with risk factors of developing BM and SREs: age, menopausal status, clinical stage, histological type, BMFI, number of BM, visceral metastases and treatment received. Our analysis also identified ER/PR/ HER2 status and KPS as prognostic factors.
Limitations, advantage and future recommendations
Along the study, we have stated that necessary quality and data comparability is not powerful enough to conduct a meta-analysis. Incidences of BM and SREs were not comparable among trials, neither were the risk factors and survival data. Nevertheless, we have been able to systematically and qualitatively review the data according to NOS guidelines and provided important information about the current real world situation. We have also underlined the need of a well-designed, retrospective and prospective study, focusing on the incidence and therapy of BM and SREs in breast cancer patients, as to better understand the efficacy of anticancer management and antiresorptive therapies in this specific breast cancer population. Open questions remain, such as an optimal time of commencing and duration of bisphosphonate therapy, influence of life-style factors (physical activity, cessation of smoking, alcohol abstinence), efficacy of supplements of Vitamin D3 and calcium etc. Long-term data on risk profiles, especially for elderly and multimorbid patients, are needed. Last but not least, so far there are no data that would correlate the BMI with possible outcomes and severity of SREs in BM patients. Same to UA In UA, BM at time of diagnosis of metastatic disease (P < 0.001), abnormal ALP value (P = 0.004), and DFI of 3-yr (P < 0.047) were statistically significant. In MA, BM at time of diagnosis of metastatic disease (P < 0.001) were statistically significant；In the nobone group, a DFI of < 3-yr were more likely to develop a SRE (P = 0.005).
SREs, skeletal-related events; BM, bone metastases; ER, estrogen receptor; PR, progesterone receptor; HER2: human epidermal growth factor receptor 2; BP, bisphosphonates; AST, aspartate transaminase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; CA153, carbohydrate antigen 153; CEA, carcino embryonie antigen; DFI, disease free interval; NA, not available. In UA, ER status (P < 0.0003), histological grade (P < 0.034), additional metastatic sites other than bone (P < 0.0004), age (P < 0.0003), number of hotspots on bone scan (P = 0.040), CA153 (P = 0.0026), CEA (P = 0.017) were found as independent prognostic factors for BoS; In MA, BMFI, additional metastatic sites other than bone, ER status and serological tumor marker levels all independently contributed to BoS. OR "Breast Neoplasm" OR "Breast Cancer" OR "Breast Carcinoma" OR "Breast Tumor*" OR "Neoplasm*, Breast" OR "Tumor*, Breast" OR "mammary carcinoma" OR "mammae cancer" OR "mammary cancer" OR "carcinoma mammae" 322520 #2 Search "Bone metastases" OR "Bone metastasis" OR "metastasis of Bone" OR "metastases of Bone" OR "Skeletal metastases" OR "Skeletal metastasis" OR "Skeletal complication*" OR "skeletal-related event*" OR "Breast Neoplasm" OR "Breast Cancer" OR "Breast Carcinoma" OR "Breast Tumor*" OR "Neoplasm*, Breast" OR "Tumor*, Breast" OR "mammary carcinoma" OR "mammae cancer" OR "mammary cancer" OR "carcinoma mammae") 438485 #2 Search TS = ("Bone metastases" OR "Bone metastasis" OR "metastasis of Bone" OR "metastases of Bone" OR "Skeletal metastases" OR "Skeletal metastasis" OR "Skeletal complication*" OR "skeletal-related event*") BoS was defined as the time from initial diagnosis of BM until death from any cause; MBoS was defined as the median time from initial diagnosis of BM until death from any cause; PFS was defined as the time interval from diagnosis of BM to progression, death, or the last follow-up date, whichever occurred first. a Survival time was calculated between start of treatment for the spinal metastasis and date of death or last follow-up moment recorded.
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